# Gamut Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gamut-therapeutics

- Industry: Biotechnology
- Headquarters: France
- Total disclosed funding: $1.2M
- Latest round: Seed (Feb 16, 2021)
- Investors on record: 1

## About

Based in France, and founded in 2020, Gamut Therapeutics operates as a gene therapy company. Gamut Therapeutics The company is a spin-out of the Institut de la Vision in Paris. The company was founded by its CSO, Deniz Dalkara. In 2021, SparingVision SAS, a portfolio company of Bpifrance, Foundation Fighting Blindness, Jeito Capital, and The University of Pittsburgh Medical Center, acquired Gamut Therapeutics from AdBio Partners.

The product line of Gamut Therapeutics includes SPVN20, which is an AAV (adeno-associated virus) vector-based gene therapy product that is used for the treatment of retinitis pigmentosa (RP). The company offers patients ocular genomic medicines that can revive dormant cone cells, which are healthy cones that have lost their ability to function because of degenerative retinal illnesses.

## Funding rounds

- Seed, Feb 16, 2021, $1.2M — AdBio Partners

## Investors

- AdBio Partners (https://capitalatlas.ai/funds/adbio-partners) — Seed